Prognostic significance of Wilms tumor 1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes

Sumiko Kobayashi, Yasunori Ueda, Yasuhito Nannya, Hirohiko Shibayama, Hideto Tamura, Kiyoyuki Ogata, Yoshiki Akatsuka, Kensuke Usuki, Yoshikazu Ito, Masaya Okada, Takahiro Suzuki, Tomoko Hata, Akira Matsuda, Kaoru Tohyama, Keiji Kakumoto, Daisuke Koga, Kinuko Mitani, Tomoki Naoe, Haruo Sugiyama, Fumimaro Takaku

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

BACKGROUND: This present study was designed to follow up 82 patients among 115 MDS patients registered in study ODK- 0801 for 5 years, to analyze the relationship between the WT1 mRNA expression level and prognosis. OBJECTIVE: This study aimed to investigate the clinical utility of WT1 mRNA expression levels. METHODS: After study ODK-0801, we investigated the conditions of the same patients once a year, including any clinical and laboratory findings supporting the diagnosis, and treatment among the living patients. RESULTS: When we assessed the survival time of 82 MDS patients by WT1 mRNA expression level, there were significant differences between the < 500 and ≥ 10 4 copies/μg RNA groups and between the 500-10 4 and ≥ 10 4 copies/μg RNA groups for BM levels (p < 0.01). Examination of the time of freedom from acute myeloid leukemia (AML) transformation indicated that a high WT1 mRNA expression level (> 104 copies/μg RNA) was a strong prognostic factor for a short time to AML transformation. CONCLUSION: The results indicate that the tumorigenesis of MDS is likely to originate at the stem cell level, suggesting that the WT1 mRNA level measurement in the BM is an effective prognostic marker in patients with MDS.

Original languageEnglish
Pages (from-to)21-32
Number of pages12
JournalCancer Biomarkers
Volume17
Issue number1
DOIs
Publication statusPublished - 01-01-2016

Fingerprint

Wilms Tumor
Myelodysplastic Syndromes
Bone Marrow
Messenger RNA
RNA
Carcinogenesis
Stem Cells
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Genetics
  • Cancer Research

Cite this

Kobayashi, Sumiko ; Ueda, Yasunori ; Nannya, Yasuhito ; Shibayama, Hirohiko ; Tamura, Hideto ; Ogata, Kiyoyuki ; Akatsuka, Yoshiki ; Usuki, Kensuke ; Ito, Yoshikazu ; Okada, Masaya ; Suzuki, Takahiro ; Hata, Tomoko ; Matsuda, Akira ; Tohyama, Kaoru ; Kakumoto, Keiji ; Koga, Daisuke ; Mitani, Kinuko ; Naoe, Tomoki ; Sugiyama, Haruo ; Takaku, Fumimaro. / Prognostic significance of Wilms tumor 1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes. In: Cancer Biomarkers. 2016 ; Vol. 17, No. 1. pp. 21-32.
@article{9e893e5ccd8645f0a4e8412a50c352a5,
title = "Prognostic significance of Wilms tumor 1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes",
abstract = "BACKGROUND: This present study was designed to follow up 82 patients among 115 MDS patients registered in study ODK- 0801 for 5 years, to analyze the relationship between the WT1 mRNA expression level and prognosis. OBJECTIVE: This study aimed to investigate the clinical utility of WT1 mRNA expression levels. METHODS: After study ODK-0801, we investigated the conditions of the same patients once a year, including any clinical and laboratory findings supporting the diagnosis, and treatment among the living patients. RESULTS: When we assessed the survival time of 82 MDS patients by WT1 mRNA expression level, there were significant differences between the < 500 and ≥ 10 4 copies/μg RNA groups and between the 500-10 4 and ≥ 10 4 copies/μg RNA groups for BM levels (p < 0.01). Examination of the time of freedom from acute myeloid leukemia (AML) transformation indicated that a high WT1 mRNA expression level (> 104 copies/μg RNA) was a strong prognostic factor for a short time to AML transformation. CONCLUSION: The results indicate that the tumorigenesis of MDS is likely to originate at the stem cell level, suggesting that the WT1 mRNA level measurement in the BM is an effective prognostic marker in patients with MDS.",
author = "Sumiko Kobayashi and Yasunori Ueda and Yasuhito Nannya and Hirohiko Shibayama and Hideto Tamura and Kiyoyuki Ogata and Yoshiki Akatsuka and Kensuke Usuki and Yoshikazu Ito and Masaya Okada and Takahiro Suzuki and Tomoko Hata and Akira Matsuda and Kaoru Tohyama and Keiji Kakumoto and Daisuke Koga and Kinuko Mitani and Tomoki Naoe and Haruo Sugiyama and Fumimaro Takaku",
year = "2016",
month = "1",
day = "1",
doi = "10.3233/CBM-160612",
language = "English",
volume = "17",
pages = "21--32",
journal = "Cancer Biomarkers",
issn = "1574-0153",
publisher = "IOS Press",
number = "1",

}

Kobayashi, S, Ueda, Y, Nannya, Y, Shibayama, H, Tamura, H, Ogata, K, Akatsuka, Y, Usuki, K, Ito, Y, Okada, M, Suzuki, T, Hata, T, Matsuda, A, Tohyama, K, Kakumoto, K, Koga, D, Mitani, K, Naoe, T, Sugiyama, H & Takaku, F 2016, 'Prognostic significance of Wilms tumor 1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes', Cancer Biomarkers, vol. 17, no. 1, pp. 21-32. https://doi.org/10.3233/CBM-160612

Prognostic significance of Wilms tumor 1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes. / Kobayashi, Sumiko; Ueda, Yasunori; Nannya, Yasuhito; Shibayama, Hirohiko; Tamura, Hideto; Ogata, Kiyoyuki; Akatsuka, Yoshiki; Usuki, Kensuke; Ito, Yoshikazu; Okada, Masaya; Suzuki, Takahiro; Hata, Tomoko; Matsuda, Akira; Tohyama, Kaoru; Kakumoto, Keiji; Koga, Daisuke; Mitani, Kinuko; Naoe, Tomoki; Sugiyama, Haruo; Takaku, Fumimaro.

In: Cancer Biomarkers, Vol. 17, No. 1, 01.01.2016, p. 21-32.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prognostic significance of Wilms tumor 1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes

AU - Kobayashi, Sumiko

AU - Ueda, Yasunori

AU - Nannya, Yasuhito

AU - Shibayama, Hirohiko

AU - Tamura, Hideto

AU - Ogata, Kiyoyuki

AU - Akatsuka, Yoshiki

AU - Usuki, Kensuke

AU - Ito, Yoshikazu

AU - Okada, Masaya

AU - Suzuki, Takahiro

AU - Hata, Tomoko

AU - Matsuda, Akira

AU - Tohyama, Kaoru

AU - Kakumoto, Keiji

AU - Koga, Daisuke

AU - Mitani, Kinuko

AU - Naoe, Tomoki

AU - Sugiyama, Haruo

AU - Takaku, Fumimaro

PY - 2016/1/1

Y1 - 2016/1/1

N2 - BACKGROUND: This present study was designed to follow up 82 patients among 115 MDS patients registered in study ODK- 0801 for 5 years, to analyze the relationship between the WT1 mRNA expression level and prognosis. OBJECTIVE: This study aimed to investigate the clinical utility of WT1 mRNA expression levels. METHODS: After study ODK-0801, we investigated the conditions of the same patients once a year, including any clinical and laboratory findings supporting the diagnosis, and treatment among the living patients. RESULTS: When we assessed the survival time of 82 MDS patients by WT1 mRNA expression level, there were significant differences between the < 500 and ≥ 10 4 copies/μg RNA groups and between the 500-10 4 and ≥ 10 4 copies/μg RNA groups for BM levels (p < 0.01). Examination of the time of freedom from acute myeloid leukemia (AML) transformation indicated that a high WT1 mRNA expression level (> 104 copies/μg RNA) was a strong prognostic factor for a short time to AML transformation. CONCLUSION: The results indicate that the tumorigenesis of MDS is likely to originate at the stem cell level, suggesting that the WT1 mRNA level measurement in the BM is an effective prognostic marker in patients with MDS.

AB - BACKGROUND: This present study was designed to follow up 82 patients among 115 MDS patients registered in study ODK- 0801 for 5 years, to analyze the relationship between the WT1 mRNA expression level and prognosis. OBJECTIVE: This study aimed to investigate the clinical utility of WT1 mRNA expression levels. METHODS: After study ODK-0801, we investigated the conditions of the same patients once a year, including any clinical and laboratory findings supporting the diagnosis, and treatment among the living patients. RESULTS: When we assessed the survival time of 82 MDS patients by WT1 mRNA expression level, there were significant differences between the < 500 and ≥ 10 4 copies/μg RNA groups and between the 500-10 4 and ≥ 10 4 copies/μg RNA groups for BM levels (p < 0.01). Examination of the time of freedom from acute myeloid leukemia (AML) transformation indicated that a high WT1 mRNA expression level (> 104 copies/μg RNA) was a strong prognostic factor for a short time to AML transformation. CONCLUSION: The results indicate that the tumorigenesis of MDS is likely to originate at the stem cell level, suggesting that the WT1 mRNA level measurement in the BM is an effective prognostic marker in patients with MDS.

UR - http://www.scopus.com/inward/record.url?scp=84978536199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978536199&partnerID=8YFLogxK

U2 - 10.3233/CBM-160612

DO - 10.3233/CBM-160612

M3 - Article

C2 - 27062571

AN - SCOPUS:84978536199

VL - 17

SP - 21

EP - 32

JO - Cancer Biomarkers

JF - Cancer Biomarkers

SN - 1574-0153

IS - 1

ER -